Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Austin Retina Associates

Neither a doctor nor a teaching hospital

Research payments

$9,059,744

1,695 payments

Through program year 2025, Austin Retina Associates is reported as receiving $9,059,744 in research payments, across 1,695 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,995,011 982
2024 Research $1,037,072 350
2023 Research $1,315,797 123
2022 Research $520,753 47
2021 Research $1,543,419 123
2020 Research $1,758,198 47
2019 Research $889,494 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $2,483,505 293 payments
  2. Novartis Pharmaceuticals Corporation $2,368,927 20 payments
  3. Regeneron Pharmaceuticals, Inc. $2,135,416 993 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $1,210,893 297 payments
  5. EyePoint Pharmaceuticals US, Inc. $585,767 6 payments
  6. Kyowa Kirin, Inc. $202,237 68 payments
  7. Aerie Pharmaceuticals, Inc. $39,876 7 payments
  8. Astellas Pharma Global Development $17,512 3 payments
  9. Allergan Inc. $6,482 5 payments
  10. Mallinckrodt Enterprises LLC $6,250 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $1,902,281 837 payments
  2. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $1,388,118 3 payments
  3. Va2 Phiii Rhine $495,537 21 payments
  4. BAY 865321, Aflibercept 8mg in RVO $425,863 207 payments
  5. A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $419,329 3 payments
  6. A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $414,497 1 payment
  7. Phase 2 of Ro7171009 in Ga $389,153 25 payments
  8. Va2 Phiii $385,856 18 payments
  9. A Phase 1 Sad MD in Diabetic MacUlar Edema $338,187 50 payments
  10. Runcaciguat Bay 1101042 - 2b in NPDR $306,456 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record